A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Diet and Exercise

Key Inclusion Criteria: * Have been diagnosed with type 2 diabetes mellitus according to the 1999 World Health Organization (WHO) criteria * Have followed dietary and exercise interventions for at least 8 weeks prior to screening * Have HbA1c ≥7.5% to ≤11.0% (screening) and ≥7.0% to ≤10.5% (pre-randomization) * Have fasting plasma glucose \<13.9 mmol/L (screening and pre-randomization) * Have a body mass index ≥18 kg/m\^2 to ≤40 kg/m\^2 Key Exclusion Criteria: * Have type 1 diabetes mellitus or specific type of diabetes mellitus (pancreatic injury-induced diabetes mellitus, diabetes mellitus caused by Cushing's syndrome or acromegaly, etc.) * Have had diabetic ketoacidosis or hyperglycemic hyperosmolar state within 6 months prior to screening * Have had 2 or more Grade 3 hypoglycemic events within 12 months prior to screening * Have unstable or treatment-requiring proliferative retinopathy or macular degeneration, severe diabetic neuropathy, diabetic foot, or intermittent claudication within 6 months prior to screening * Have been taking any weight loss medication or dietary supplement, have participated in a weight loss program, or have adhered to a special diet within 4 weeks prior to screening * Have continuously used insulin or an insulin analogue for more than 14 days within 12 months prior to screening * Have used 2 or more classes of hypoglycemic medications for more than 8 weeks within 12 months prior to screening * Have used any glucose-modifying medications within 8 weeks prior to screening * Have had weight gain or loss ≥5% from screening to randomization